"Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study

G. Brusselle, A. Michils, R. Louis, L. Dupont, B. Van de Maele, A. Delobbe, C. Pilette, Christopher Lee, S. Gurdain, S. Vancayzeele, P. Lecomte, C. Hermans, K. MacDonald, MinKyoung Song, I. Abraham

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Objective: To evaluate the 16- and 52-week effectiveness of add-on omalizumab treatment under real-life heterogeneity in patients, settings, and physicians in an open-label, multicenter, pharmaco-epidemiologic study of patients with severe persistent allergic asthma in Belgium. Methods: Effectiveness outcomes included improvement in 2005 global initiative for asthma (GINA) classification, physician-rated global evaluation of treatment effectiveness (GETE), quality of life (Juniper asthma-related quality of life (AQLQ) and European quality of life questionnaire 5 dimensions (EQ-5D)), and severe asthma exacerbations. Patients studied included both intent-to-treat and per-protocol populations. Results: The sample (n = 158) had a mean age of 48.17 ± 17.18 years, and a slight majority were female (53.8%). Despite being treated with high-dose inhaled corticosteroids and long-acting β2-agonists, all patients experienced frequent symptoms and had exacerbations in the past year. At 16 weeks, >82% had good/excellent GETE (P values 82% had an improvement in total AQLQ scores of ≥0.5 points (P <0.001), and >91% were severe exacerbation-free (P <0.001). At 52 weeks, >72% had a good/excellent GETE rating (P <0.001), >84% had improvements in total AQLQ score of ≥0.5 points (P <0.001), >56% had minimally important improvements in EQ-5D utility scores (P = 0.012), and >65% were severe exacerbation-free (P <0.001). Significant reductions in healthcare utilization compared to the one year prior to treatment were noted. Conclusion: The PERSIST study shows better physician-rated effectiveness, greater improvements in quality of life, greater reductions in exacerbation rates, and greater reductions in healthcare utilization than previously reported in efficacy studies. Under real-life conditions, omalizumab is effective as add-on therapy in the treatment of patients with persistent severe allergic asthma.

Original languageEnglish (US)
Pages (from-to)1633-1642
Number of pages10
JournalRespiratory Medicine
Volume103
Issue number11
DOIs
StatePublished - Nov 2009
Externally publishedYes

Fingerprint

Asthma
Quality of Life
Physicians
Juniperus
Delivery of Health Care
Belgium
Therapeutics
Epidemiologic Studies
Adrenal Cortex Hormones
Omalizumab
Population

Keywords

  • Allergic asthma
  • Asthma
  • Omalizumab
  • Severe asthma

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Brusselle, G., Michils, A., Louis, R., Dupont, L., Van de Maele, B., Delobbe, A., ... Abraham, I. (2009). "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respiratory Medicine, 103(11), 1633-1642. https://doi.org/10.1016/j.rmed.2009.06.014

"Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma : The PERSIST study. / Brusselle, G.; Michils, A.; Louis, R.; Dupont, L.; Van de Maele, B.; Delobbe, A.; Pilette, C.; Lee, Christopher; Gurdain, S.; Vancayzeele, S.; Lecomte, P.; Hermans, C.; MacDonald, K.; Song, MinKyoung; Abraham, I.

In: Respiratory Medicine, Vol. 103, No. 11, 11.2009, p. 1633-1642.

Research output: Contribution to journalArticle

Brusselle, G, Michils, A, Louis, R, Dupont, L, Van de Maele, B, Delobbe, A, Pilette, C, Lee, C, Gurdain, S, Vancayzeele, S, Lecomte, P, Hermans, C, MacDonald, K, Song, M & Abraham, I 2009, '"Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study', Respiratory Medicine, vol. 103, no. 11, pp. 1633-1642. https://doi.org/10.1016/j.rmed.2009.06.014
Brusselle, G. ; Michils, A. ; Louis, R. ; Dupont, L. ; Van de Maele, B. ; Delobbe, A. ; Pilette, C. ; Lee, Christopher ; Gurdain, S. ; Vancayzeele, S. ; Lecomte, P. ; Hermans, C. ; MacDonald, K. ; Song, MinKyoung ; Abraham, I. / "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma : The PERSIST study. In: Respiratory Medicine. 2009 ; Vol. 103, No. 11. pp. 1633-1642.
@article{91375b5ce8244130a3efa5ed7fb53095,
title = "{"}Real-life{"} effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study",
abstract = "Objective: To evaluate the 16- and 52-week effectiveness of add-on omalizumab treatment under real-life heterogeneity in patients, settings, and physicians in an open-label, multicenter, pharmaco-epidemiologic study of patients with severe persistent allergic asthma in Belgium. Methods: Effectiveness outcomes included improvement in 2005 global initiative for asthma (GINA) classification, physician-rated global evaluation of treatment effectiveness (GETE), quality of life (Juniper asthma-related quality of life (AQLQ) and European quality of life questionnaire 5 dimensions (EQ-5D)), and severe asthma exacerbations. Patients studied included both intent-to-treat and per-protocol populations. Results: The sample (n = 158) had a mean age of 48.17 ± 17.18 years, and a slight majority were female (53.8{\%}). Despite being treated with high-dose inhaled corticosteroids and long-acting β2-agonists, all patients experienced frequent symptoms and had exacerbations in the past year. At 16 weeks, >82{\%} had good/excellent GETE (P values 82{\%} had an improvement in total AQLQ scores of ≥0.5 points (P <0.001), and >91{\%} were severe exacerbation-free (P <0.001). At 52 weeks, >72{\%} had a good/excellent GETE rating (P <0.001), >84{\%} had improvements in total AQLQ score of ≥0.5 points (P <0.001), >56{\%} had minimally important improvements in EQ-5D utility scores (P = 0.012), and >65{\%} were severe exacerbation-free (P <0.001). Significant reductions in healthcare utilization compared to the one year prior to treatment were noted. Conclusion: The PERSIST study shows better physician-rated effectiveness, greater improvements in quality of life, greater reductions in exacerbation rates, and greater reductions in healthcare utilization than previously reported in efficacy studies. Under real-life conditions, omalizumab is effective as add-on therapy in the treatment of patients with persistent severe allergic asthma.",
keywords = "Allergic asthma, Asthma, Omalizumab, Severe asthma",
author = "G. Brusselle and A. Michils and R. Louis and L. Dupont and {Van de Maele}, B. and A. Delobbe and C. Pilette and Christopher Lee and S. Gurdain and S. Vancayzeele and P. Lecomte and C. Hermans and K. MacDonald and MinKyoung Song and I. Abraham",
year = "2009",
month = "11",
doi = "10.1016/j.rmed.2009.06.014",
language = "English (US)",
volume = "103",
pages = "1633--1642",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "11",

}

TY - JOUR

T1 - "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma

T2 - The PERSIST study

AU - Brusselle, G.

AU - Michils, A.

AU - Louis, R.

AU - Dupont, L.

AU - Van de Maele, B.

AU - Delobbe, A.

AU - Pilette, C.

AU - Lee, Christopher

AU - Gurdain, S.

AU - Vancayzeele, S.

AU - Lecomte, P.

AU - Hermans, C.

AU - MacDonald, K.

AU - Song, MinKyoung

AU - Abraham, I.

PY - 2009/11

Y1 - 2009/11

N2 - Objective: To evaluate the 16- and 52-week effectiveness of add-on omalizumab treatment under real-life heterogeneity in patients, settings, and physicians in an open-label, multicenter, pharmaco-epidemiologic study of patients with severe persistent allergic asthma in Belgium. Methods: Effectiveness outcomes included improvement in 2005 global initiative for asthma (GINA) classification, physician-rated global evaluation of treatment effectiveness (GETE), quality of life (Juniper asthma-related quality of life (AQLQ) and European quality of life questionnaire 5 dimensions (EQ-5D)), and severe asthma exacerbations. Patients studied included both intent-to-treat and per-protocol populations. Results: The sample (n = 158) had a mean age of 48.17 ± 17.18 years, and a slight majority were female (53.8%). Despite being treated with high-dose inhaled corticosteroids and long-acting β2-agonists, all patients experienced frequent symptoms and had exacerbations in the past year. At 16 weeks, >82% had good/excellent GETE (P values 82% had an improvement in total AQLQ scores of ≥0.5 points (P <0.001), and >91% were severe exacerbation-free (P <0.001). At 52 weeks, >72% had a good/excellent GETE rating (P <0.001), >84% had improvements in total AQLQ score of ≥0.5 points (P <0.001), >56% had minimally important improvements in EQ-5D utility scores (P = 0.012), and >65% were severe exacerbation-free (P <0.001). Significant reductions in healthcare utilization compared to the one year prior to treatment were noted. Conclusion: The PERSIST study shows better physician-rated effectiveness, greater improvements in quality of life, greater reductions in exacerbation rates, and greater reductions in healthcare utilization than previously reported in efficacy studies. Under real-life conditions, omalizumab is effective as add-on therapy in the treatment of patients with persistent severe allergic asthma.

AB - Objective: To evaluate the 16- and 52-week effectiveness of add-on omalizumab treatment under real-life heterogeneity in patients, settings, and physicians in an open-label, multicenter, pharmaco-epidemiologic study of patients with severe persistent allergic asthma in Belgium. Methods: Effectiveness outcomes included improvement in 2005 global initiative for asthma (GINA) classification, physician-rated global evaluation of treatment effectiveness (GETE), quality of life (Juniper asthma-related quality of life (AQLQ) and European quality of life questionnaire 5 dimensions (EQ-5D)), and severe asthma exacerbations. Patients studied included both intent-to-treat and per-protocol populations. Results: The sample (n = 158) had a mean age of 48.17 ± 17.18 years, and a slight majority were female (53.8%). Despite being treated with high-dose inhaled corticosteroids and long-acting β2-agonists, all patients experienced frequent symptoms and had exacerbations in the past year. At 16 weeks, >82% had good/excellent GETE (P values 82% had an improvement in total AQLQ scores of ≥0.5 points (P <0.001), and >91% were severe exacerbation-free (P <0.001). At 52 weeks, >72% had a good/excellent GETE rating (P <0.001), >84% had improvements in total AQLQ score of ≥0.5 points (P <0.001), >56% had minimally important improvements in EQ-5D utility scores (P = 0.012), and >65% were severe exacerbation-free (P <0.001). Significant reductions in healthcare utilization compared to the one year prior to treatment were noted. Conclusion: The PERSIST study shows better physician-rated effectiveness, greater improvements in quality of life, greater reductions in exacerbation rates, and greater reductions in healthcare utilization than previously reported in efficacy studies. Under real-life conditions, omalizumab is effective as add-on therapy in the treatment of patients with persistent severe allergic asthma.

KW - Allergic asthma

KW - Asthma

KW - Omalizumab

KW - Severe asthma

UR - http://www.scopus.com/inward/record.url?scp=70349621577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349621577&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2009.06.014

DO - 10.1016/j.rmed.2009.06.014

M3 - Article

C2 - 19619998

AN - SCOPUS:70349621577

VL - 103

SP - 1633

EP - 1642

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 11

ER -